SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure-A Concise Review

• Published in: Journal of clinical medicine Vol. 11; no. 6; p. 1470
• Main Authors: Keller, Daria M, Ahmed, Natasha, Tariq, Hamza, Walgamage, Malsha, Walgamage, Thilini, Mohammed, Azad, Chou, Jadzia Tin-Tsen, Kałużna-Oleksy, Marta, Lesiak, Maciej, Straburzyńska-Migaj, Ewa
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.03.2022; MDPI
• Subjects: Antidiabetics; Clinical medicine; Contraindications; COVID-19; Diabetes; Disease; Drug dosages; Ejection fraction; FDA approval; Glucose; Heart failure; Insulin resistance; Kidneys; Mortality; Oxidative stress; Physiology; Review; Sodium; heart failure; sodium-glucose co-transporter 2 inhibitors; sodium-glucose co-transporter 2; diabetes mellitus type 2

The incidence of both diabetes mellitus type 2 and heart failure is rapidly growing, and the diseases often coexist. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new antidiabetic drug class that mediates epithelial glucose transport at the renal proximal tubules, inhibiting glucose abso...